|
Post by patten1962 on Jan 25, 2017 11:04:35 GMT -5
I think it's safe to say that MannKind does not want the Delisting of this stock as much as we don't want it. I am still in shock that the sanofi exit deal did not move us over a dollar. A great many investors on this page and others like to beat up Matt for the way he does his job. The glass is half empty. I would like to say the glass is half-full. I believe Matt has done a good job keeping this company afloat with everything that happened with sanofi. The original deal with sanofi was a very bad move and we all know this now. It's time to move forward and I truly believe we will be getting some news soon that will help our share price. Good luck all Longs! There is a huge difference in keeping the company afloat (which honestly many CFO's can do) and actually building out a successful vision and business model which MNKD has so far failed at. They need to do this at an unparalleled rate which unfortunately the chance of them failing is probably greater than succeeding that is just the reality. Shareholders just can't wait anymore for the magical rabbit that has been talked about for years. Our investment decisions are on us no doubt about that but that doesn't mean we can't be critical of the company's decisions and management. On the contrary you can be critical all you want. That is your right. Fortunately for me I have only been invested in MannKind for about 14 months. I truly do believe this is investment opportunity of a lifetime. I was just trying to give an opposing viewpoint, I believe Matt is doing a good job. No, I am not an executive with any company. I am just a healthcare worker who has a little extra money to invest. Many of the people that I have faith in believe in MannKind, technosphere and Afrezza. Even though I take a shot now and then for my perceived ignorance in the stock market, I really do like this board because I get some valuable information. I just believe sometimes the very intelligent do not understand some people do not have the backgrounds that they have I need to ask questions.
|
|
|
Post by agedhippie on Jan 25, 2017 12:03:40 GMT -5
It may have been Al's desire for Matt to be the CEO. Obviously, he is proceeding cautiously, almost intentionally; perhaps he knows something that can not be revealed yet. why was Duane DeSisto announced as a ceo and not Matt? Did Al had no choice and put Matt in the chair? I wondered at the time if Matt had originally applied for the CEO role but DeSisto was obviously far better qualified and got the job. Then when DeSisto fell through Al gave it to Matt thinking that Matt could grow into the role with support which unfortunately was cut short. Now you have Matt in a role he isn't really qualified for and learning on the job without Al there to support him.
|
|
|
Post by dreamboatcruise on Jan 25, 2017 13:27:21 GMT -5
Matt Pfeffer is a great guy, but I really don't think he understands that he has allowed his dual role of CFO-CEO to usurp his duties to be a full time CEO, which entails becoming the face of the company. This CEO needs to be participating in industry discussion panels talking about current issues related to insulin treatment and epinephrine. He needs to be getting his picture taken with kids, talking about the upcoming Afrezza pediatric trials and making statements (for the press to report) about how Afrezza has the potential to revolutionize the treatment of children with diabetes and how eager and excited the company is to be starting its pediatric trial of Afrezza. However, by isolating himself behind his desk, CEO Pfeffer is isolating MannKind from the medical community, from Wall Street, from patients and from potential partners/collaborators. I honestly wonder if he has a clue as to what constitutes the type of value that motivates Wall Street to invest in a company stock. If he did, this CEO would be traveling all over the country promoting Technosphere insulin, the technology itself and promoting a low-cost inhaled epinephrine. He should be promoting a low-cost Afrezza as well, but management shot that horse and all the publicity that could have accompanied an announcement of a price cut when Afrezza was returned by Sanofi. In my opinion the BoD, rather than hire an experienced and assertive CEO who will get out there, be the face of MannKind and and show what this company has to offer to the world, instead promoted their CFO. Matt Pfeffer, as CEO of MannKind Corporation, needs to be right in the middle of the diabetes community engaging the KOLs, getting involved in the discussions and providing Wall Street with a clear understanding of real value of MannKind's drug, drug platform and drug pipeline. Relying on the occasional investor conference, earning calls and a booth at the ADA to promote the value of MannKind Corporation is simply insufficient, IMO. It would be interesting if MNKD could thrust itself into a leading role championing long term outcome based medicine (long term view of cost savings) focused on the specifics of early insulin intervention for diabetes. Whether it is Matt or someone else in MNKD best suited, I wouldn't weigh in on.
|
|
|
Post by lsl428 on Jan 25, 2017 15:05:37 GMT -5
On the subject of a RS....if they were to do even a 2 to 1 RS and NOT do a capital raise.....then the price might hold.... reason being is ultimately the market cap....if stock was to be sold under a dollar from where it is today the market cap would go from 300 million currently to under 200 or less...at some point there is residual value so share price might be protected....
|
|
|
Post by BlueCat on Jan 25, 2017 16:35:02 GMT -5
On the subject of a RS....if they were to do even a 2 to 1 RS and NOT do a capital raise.....then the price might hold.... reason being is ultimately the market cap....if stock was to be sold under a dollar from where it is today the market cap would go from 300 million currently to under 200 or less...at some point there is residual value so share price might be protected.... For a recent example of that not working so well for a market opportunity that is still pretty good with a good tech to address it, try looking at VMEM and how that worked out for them.
|
|